Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTL0812 in combination with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer
NCT03417921Phase 2Suspended
- Sponsor
- AbilityPharma
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrilatazar in pancreatic cancer (PC), sponsored by AbilityPharma. Started Apr 2021; status: suspended.
02
Drugs
ibrilatazar
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03417921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417921.